Hematopoietic Cell Growth Factors
"Hematopoietic Cell Growth Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
These growth factors comprise a family of hematopoietic regulators with biological specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. ERYTHROPOIETIN and the COLONY-STIMULATING FACTORS belong to this family. Some of these factors have been studied and used in the treatment of chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes.
Below are MeSH descriptors whose meaning is more general than "Hematopoietic Cell Growth Factors".
Below are MeSH descriptors whose meaning is more specific than "Hematopoietic Cell Growth Factors".
This graph shows the total number of publications written about "Hematopoietic Cell Growth Factors" by people in this website by year, and whether "Hematopoietic Cell Growth Factors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Hematopoietic Cell Growth Factors" by people in Profiles.
Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, Stuart RK. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant. 2011 Apr; 46(4):523-8.
Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006 Dec; 135(5):642-50.
Ogawa M. Stochastic model revisited. Int J Hematol. 1999 Jan; 69(1):2-5.
Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood. 1996 Jul 15; 88(2):429-36.
Fujimoto K, Lyman SD, Hiryama F, Ogawa M. Isolation and characterization of primitive hematopoietic progenitors of murine fetal liver. Exp Hematol. 1996 Feb; 24(2):285-90.
Kobayashi M, Laver JH, Kato T, Miyazaki H, Ogawa M. Recombinant human thrombopoietin (Mpl ligand) enhances proliferation of erythroid progenitors. Blood. 1995 Oct 01; 86(7):2494-9.
Ball TC, Hirayama F, Ogawa M. Lymphohematopoietic progenitors of normal mice. Blood. 1995 Jun 01; 85(11):3086-92.
Hirayama F, Lyman SD, Clark SC, Ogawa M. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood. 1995 Apr 01; 85(7):1762-8.
Traycoff CM, Abboud MR, Laver J, Clapp DW, Srour EF. Rapid exit from G0/G1 phases of cell cycle in response to stem cell factor confers on umbilical cord blood CD34+ cells an enhanced ex vivo expansion potential. Exp Hematol. 1994 Dec; 22(13):1264-72.
Bennett CL, Armitage JL, LeSage S, Gulati SC, Armitage JO, Gorin NC. Economic analyses of clinical trials in cancer: are they helpful to policy makers? Stem Cells. 1994 Jul; 12(4):424-9.